As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh carries a market capitalization of 48.90B, placing it among publicly traded companies globally. Its enterprise value stands at 47.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 48.90B |
| Enterprise Value | 47.90B |
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh's next confirmed earnings release is scheduled for February 10, 2027.
| Earnings Date | 2/10/2027 |
As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh has 1.15B shares outstanding.
| Shares Outstanding | 1.15B |
These figures are as of September 30, 2026. The price-to-sales ratio is 20.80, and the price-to-book ratio stands at 187.53.
| PS Ratio | 20.80 |
| PB Ratio | 187.53 |
| P/TBV Ratio | 208.96 |
| P/FCF Ratio | -33.25 |
| P/OCF Ratio | -34.49 |
These figures are as of September 30, 2026. The EV/Sales ratio of 20.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 47.90B versus a market cap of 48.90B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 20.50 |
As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh maintains a current ratio of 4.14, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,980.43, indicating moderate leverage, while an interest coverage ratio of -7.26 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.14 |
| Quick Ratio | 3.86 |
| Debt / Equity | 1,980.43 |
| Debt / EBITDA | -1.47 |
| Interest Coverage | -7.26 |
Over the twelve months ended September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh posted a negative return on equity (ROE) of -280.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.37, reflecting losses generated across the asset base. The company generates approximately 2.93M in revenue per employee across its workforce of 798.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -280.50 |
| Return on Assets (ROA) | -46.37 |
| Revenue Per Employee | 2.93M |
| Employee Count | 798.00 |
Over the twelve months ended September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh recorded an income tax benefit of -35.14M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -3.75B and -3.75B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -35.14M |
As of the close on November 16, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh's stock has gained approximately 22.73% over the past 52 weeks. The 50-day moving average sits at 45.52, while the 200-day moving average is 45.66.
| 52-Week Price Change | 22.73% |
| 50-Day Moving Average | 45.52 |
| 200-Day Moving Average | 45.66 |
Over the twelve months ended September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh generated 2.34B in revenue and converted that into -3.75B in net income, yielding earnings per share of -3.23. EBITDA reached -3.53B, while operating income came in at -3.66B.
| Revenue | 2.34B |
| Operating Income | -3.66B |
| Pretax Income | -3.75B |
| Net Income | -3.75B |
| EBITDA | -3.53B |
| EBIT | -3.66B |
| Earnings Per Share (EPS) | -3.23 |
As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh holds 6.18B in cash and equivalents against 5.18B in total debt, resulting in a net debt position of 4.23B. Total book value stands at 260.75M, with working capital of 5.07B providing operational flexibility.
| Cash & Cash Equivalents | 6.18B |
| Total Debt | 5.18B |
| Net Debt | 4.23B |
| Equity (Book Value) | 260.75M |
| Book Value Per Share | 0.23 |
| Working Capital | 5.07B |
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh produced -1.41B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -62.16M in capital expenditures, free cash flow totaled -1.47B - equivalent to -1.29 per share.
| Operating Cash Flow | -1.41B |
| Capital Expenditures | -62.16M |
| Free Cash Flow | -1.47B |
| FCF Per Share | -1.29 |
These figures cover the twelve months ended September 30, 2026. The operating margin of -156.86 and net profit margin of -160.64 provide insight into operational efficiency.
| Operating Margin | -156.86 |
| Pretax Margin | -160.58 |
| Profit Margin | -160.64 |
| EBITDA Margin | -150.96 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -3.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.23, meaning Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -8.23 |
| FCF Yield | -3.01 |
As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh has an Altman Z-Score of 1.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.05 |